MedTrace Logo

Pulmonary Artery Remodelling With Bosentan

NCT00595049 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2025-02-03

No results posted yet for this study

Summary

The main purpose of this study is to investigate whether bosentan (Tracleer®) affects the wall thickness of the pulmonary arteries in patients with idiopathic pulmonary arterial hypertension (iPAH) and PAH related to systemic sclerosis (PAH-SSc).

The second purpose is to investigate if bosentan affects the enlargement of small vessels in the lungs in response to natural chemicals in patients with iPAH and PAH-SSc.

Conditions

  • Hypertension, Pulmonary

Interventions

DRUG

bosentan

Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid

Sponsors & Collaborators

  • Actelion

    lead INDUSTRY

Principal Investigators

  • David Celermajer, Professor · Royal Prince Alfred Hospital, Camperdown

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-12-31
Completion
2010-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00595049 on ClinicalTrials.gov